HEMACARE ist die letzten Tage explodiert!!!!!!!!!!!!! - 500 Beiträge pro Seite
eröffnet am 12.09.04 22:11:45 von
neuester Beitrag 25.03.05 21:57:13 von
neuester Beitrag 25.03.05 21:57:13 von
Beiträge: 33
ID: 902.962
ID: 902.962
Aufrufe heute: 0
Gesamt: 706
Gesamt: 706
Aktive User: 0
ISIN: US4234981045 · WKN: 922675
25,31
USD
+0,60 %
+0,15 USD
Letzter Kurs 04.01.20 Nasdaq OTC
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7113 | +21,90 | |
| 0,6400 | +18,52 | |
| 1,1100 | +15,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Feedback
Business Summary: CURRENT BUSINESS INFORMATION: HemaCare Corporation, Inc. collects, processes and distributes blood products to hospitals in the United States. Additionally, the Company provides blood-related services (“therapeutic apheresis” or “TA”), on a mobile basis, to patients with a variety of disorders. The Company is the only investor-owned and taxable organization operating as a blood supplier with significant operations in the United States. The Company’s customers include university teaching hospitals, medical centers and regional hospitals located in California, Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, North Carolina, Rhode Island, Tennessee, and West Virginia.
JS200
JS200
HEMA
HEMACARE CP
Daily Commentary
Our system posted a BUY CONFIRMED today. The previous SELL recommendation that was confirmed was made on 09.07.2004 (5) days ago, when the stock price was 0.8300. Since then HEMA has gained 62.65% .
Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.
Don`t worry if you have missed this buying opportunity. The market may now give you a second chance. You may still find good prices for buying in the next session.
[MOTTO OF THE DAY]
Buying was right in a nice bullish day
Hold your stocks now whatever they say
BUY
CONFIRMED
1.3500
+0.3400 +33.66%
Candlestick Analysis
Today’s Candlestick Patterns:
White Opening Marubozu
Today a White Opening Marubozu was formed. This shows that the day opened and then the prices continued to go up all day long without coming below the opening level thus forming a long white body, however prices did not close at the high of the day and thus they created an upper shadow.
For more about this candlestick click here.
Stock Quote
Day`s Close 1.3500
Previous Close 1.0100
Previous Open 1.0000
Change +0.3400
% Change +33.66%
Volume 156,542
Stock Activity
Day`s Open 1.0300
Day`s High 1.3800
Day`s Low 1.0250
50-Day Close M.A. 0.7628
200-Day Close M.A. 0.7296
65-Day Volume M.A. 13,196
JS200
HEMACARE CP
Daily Commentary
Our system posted a BUY CONFIRMED today. The previous SELL recommendation that was confirmed was made on 09.07.2004 (5) days ago, when the stock price was 0.8300. Since then HEMA has gained 62.65% .
Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.
Don`t worry if you have missed this buying opportunity. The market may now give you a second chance. You may still find good prices for buying in the next session.
[MOTTO OF THE DAY]
Buying was right in a nice bullish day
Hold your stocks now whatever they say
BUY
CONFIRMED
1.3500
+0.3400 +33.66%
Candlestick Analysis
Today’s Candlestick Patterns:
White Opening Marubozu
Today a White Opening Marubozu was formed. This shows that the day opened and then the prices continued to go up all day long without coming below the opening level thus forming a long white body, however prices did not close at the high of the day and thus they created an upper shadow.
For more about this candlestick click here.
Stock Quote
Day`s Close 1.3500
Previous Close 1.0100
Previous Open 1.0000
Change +0.3400
% Change +33.66%
Volume 156,542
Stock Activity
Day`s Open 1.0300
Day`s High 1.3800
Day`s Low 1.0250
50-Day Close M.A. 0.7628
200-Day Close M.A. 0.7296
65-Day Volume M.A. 13,196
JS200
Die falsche ist explodiert,FONX
Langsam zurück kommen lassen und dann rein
JS200
JS200
HEMA: New 52-Wk High @ $1.380 up 2.22%
Wednesday, September 15, 2004 11:46 ET
This is the 2nd 52 WEEK HIGH alert for HEMA in the past 7 calendar days.
The share price for HemaCare Corporation (OTCBB: HEMA) reached a new 52-week high today, trading at $1.380, up $0.030 (2.22%) from its previous close of $1.350.
The Company`s previous 52-week high of $1.380 was set 5 days ago on September 10, 2004.
One year ago, the Company`s shares closed at $0.750. The price has climbed more than 83 percent since then.
At the time of this alert, the stock had traded 7,900 shares via 4 trades, 58.41% below it`s 20day average of 18,993 shares.
This new 52-week high currently puts the stock:
44.88% above its 20day Moving Average of $0.953
76.34% above its 50day Moving Average of $0.783
81.80% above its 100day Moving Average of $0.759
The Company last released news on August 13, 2004:
"HemaCare Reports Second Quarter Financial Results"
HEMACARE CORPORATION
HemaCare Corporation, Inc. collects, processes and distributes blood products to hospitals in the United States. Additionally, the Company provides blood-related services (“therapeutic apheresis” or “TA”), on a mobile basis, to patients with a variety of disorders. The Company is the only investor-owned and taxable organization operating as a blood supplier with significant operations in the United States. The Company’s customers include university teaching hospitals, medical centers and regional hospitals located in California, Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, North Carolina, Rhode Island, Tennessee, and West Virginia.
JS200
Wednesday, September 15, 2004 11:46 ET
This is the 2nd 52 WEEK HIGH alert for HEMA in the past 7 calendar days.
The share price for HemaCare Corporation (OTCBB: HEMA) reached a new 52-week high today, trading at $1.380, up $0.030 (2.22%) from its previous close of $1.350.
The Company`s previous 52-week high of $1.380 was set 5 days ago on September 10, 2004.
One year ago, the Company`s shares closed at $0.750. The price has climbed more than 83 percent since then.
At the time of this alert, the stock had traded 7,900 shares via 4 trades, 58.41% below it`s 20day average of 18,993 shares.
This new 52-week high currently puts the stock:
44.88% above its 20day Moving Average of $0.953
76.34% above its 50day Moving Average of $0.783
81.80% above its 100day Moving Average of $0.759
The Company last released news on August 13, 2004:
"HemaCare Reports Second Quarter Financial Results"
HEMACARE CORPORATION
HemaCare Corporation, Inc. collects, processes and distributes blood products to hospitals in the United States. Additionally, the Company provides blood-related services (“therapeutic apheresis” or “TA”), on a mobile basis, to patients with a variety of disorders. The Company is the only investor-owned and taxable organization operating as a blood supplier with significant operations in the United States. The Company’s customers include university teaching hospitals, medical centers and regional hospitals located in California, Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, North Carolina, Rhode Island, Tennessee, and West Virginia.
JS200
Trading Spotlight
Sollte jemand Interesse haben
WKN: 922675 ISIN: US4234981045
JS200
WKN: 922675 ISIN: US4234981045
JS200
Name
Typ
Aktuell
Währg.
Diff.
Datum
Zeit
Börse
HEMACARE CORP Aktie 1,28 USD -5,19% 15.09.04 18:49 NASDAQ OTC BBS
HEMACARE CORP. Regis.. Aktie 1,02 EUR +6,25% 15.09.04 09:07 Berlin-Bremen
Typ
Aktuell
Währg.
Diff.
Datum
Zeit
Börse
HEMACARE CORP Aktie 1,28 USD -5,19% 15.09.04 18:49 NASDAQ OTC BBS
HEMACARE CORP. Regis.. Aktie 1,02 EUR +6,25% 15.09.04 09:07 Berlin-Bremen
So langsam kommt Sie zurück wie im Posting 4 beschrieben
Unterstützung bei 1,00
Das sollte der Einstiegspunkt sein
JS200
Unterstützung bei 1,00
Das sollte der Einstiegspunkt sein
JS200
HEMA: New 52-Wk High @ $1.410 up 15.57%
Monday , September 20, 2004 10:50 ET
This is the 2nd 52 WEEK HIGH alert for HEMA in the past 7 calendar days.
The share price for HemaCare Corporation (OTCBB: HEMA) reached a new 52-week high today, trading at $1.410, up $0.190 (15.57%) from its previous close of $1.220.
The Company`s previous 52-week high of $1.390 was set 5 days ago on September 15, 2004.
One year ago, the Company`s shares closed at $0.650. The price has climbed more than 116 percent since then.
At the time of this alert, the stock had traded 63,600 shares via 11 trades, 239.13% above it`s 20day average of 18,754 shares.
This new 52-week high currently puts the stock:
40.09% above its 20day Moving Average of $1.006
73.86% above its 50day Moving Average of $0.811
82.02% above its 100day Moving Average of $0.775
The Company last released news on August 13, 2004:
"HemaCare Reports Second Quarter Financial Results"
HEMACARE CORPORATION
HemaCare Corporation, Inc. collects, processes and distributes blood products to hospitals in the United States. Additionally, the Company provides blood-related services (“therapeutic apheresis” or “TA”), on a mobile basis, to patients with a variety of disorders. The Company is the only investor-owned and taxable organization operating as a blood supplier with significant operations in the United States. The Company’s customers include university teaching hospitals, medical centers and regional hospitals located in California, Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, North Carolina, Rhode Island, Tennessee, and West Virginia.
JS200
Monday , September 20, 2004 10:50 ET
This is the 2nd 52 WEEK HIGH alert for HEMA in the past 7 calendar days.
The share price for HemaCare Corporation (OTCBB: HEMA) reached a new 52-week high today, trading at $1.410, up $0.190 (15.57%) from its previous close of $1.220.
The Company`s previous 52-week high of $1.390 was set 5 days ago on September 15, 2004.
One year ago, the Company`s shares closed at $0.650. The price has climbed more than 116 percent since then.
At the time of this alert, the stock had traded 63,600 shares via 11 trades, 239.13% above it`s 20day average of 18,754 shares.
This new 52-week high currently puts the stock:
40.09% above its 20day Moving Average of $1.006
73.86% above its 50day Moving Average of $0.811
82.02% above its 100day Moving Average of $0.775
The Company last released news on August 13, 2004:
"HemaCare Reports Second Quarter Financial Results"
HEMACARE CORPORATION
HemaCare Corporation, Inc. collects, processes and distributes blood products to hospitals in the United States. Additionally, the Company provides blood-related services (“therapeutic apheresis” or “TA”), on a mobile basis, to patients with a variety of disorders. The Company is the only investor-owned and taxable organization operating as a blood supplier with significant operations in the United States. The Company’s customers include university teaching hospitals, medical centers and regional hospitals located in California, Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, North Carolina, Rhode Island, Tennessee, and West Virginia.
JS200
Last Trade: 1.390 Change: 0.170 (+13.934%)
Previous Close: 1.220 Volume: 71,600
Bid: 1.350 Ask: 1.420
Today`s Open: 1.200 # of Trades: 15
Previous Close: 1.220 Volume: 71,600
Bid: 1.350 Ask: 1.420
Today`s Open: 1.200 # of Trades: 15
5. HOT STOCKS INVESTOR
Einen hochexplosiven und exklusiven Titel, den spekulative Investoren ins Visier nehmen sollten, ist HEMACARE! Die kleine Gesellschaft aus Los Angeles ist im breiten Markt in der Tat so gut wie unbekannt. Kein Zufall, wird der Titel doch nur am OTC gehandelt und mit einer Market Cap von USD 7,8 Mio. im Bereich von Erinnerungswerten bewertet. Schaut man auf die fundamentale Entwicklung der letzten Jahre, verwundert das nicht, denn der Blutbankdienstleister schlitterte aufgrund problematischer Expansionsentscheidungen in eine herbe Krise, die im Vorjahr einen einschneidenden Restrukturierungskurs mit Verlusten von USD 4,7 Mio. mit sich brachte. Doch genau der zahlt sich nun aus: Die letzten drei Quartale schrieb man bei HEMACARE nun wieder zunehmend solide schwarze Zahlen: Im Q4 2003 noch USD 264`000, im Q2 2004 waren es jetzt schon USD 488`000 – damit war das Q2 jetzt das profitabelste Quartal der Gesellschaft seit dem Q4 2000! Auf Vorsteuerbasis sogar das profitabelste Quartals seit 15 Jahren. Das sieht also nach einem ordentlich gelungenen Turnaround aus. Den hat man erreicht durch Schliessungen von unrentablen Blutbanken und Fokussierung auf das Core-Business. Dadurch wird verdeckt, dass in diesen Kernbereichen auch die Umsätze sich solide entwickeln. In der Gesamtrechung zeigt sich da zwar mit Quartalsumsätzen von knapp USD 7 nicht viel im Vorjahresvergleich, betrachtet man aber die Entwicklung allein der fortgeführten Businessbereiche, verzeichnet man z.B. beim Verkauf von Blutprodukten Gewinne von über 20% zum Vorjahr! Da zahlen sich also massive Effizienzgewinne aus und die will man weiter ausbauen. Zwar hat man keine Guidance für das laufende Jahr geliefert, rechnet man aber die Entwicklung des ersten Halbjahres auf Jahresbasis hoch, erscheint ein Gewinn bei einer konservativen Schätzung von USD 1,5 Mio. als erreichbar. Bei einer optimistischen Schätzung auf der Basis allein der aktuellen Q2 Zahlen wären vielleicht sogar bis zu USD 2 Mio. drin. Und das bei einer aktuellen Market Cap von USD 7,8 Mio. – da können Sie ausrechnen, was das für einer Marktbewertung entspricht: KUV um 0,3 und KGV von 4-5. Angesichts der geringen Market Cap ist der Titel kein Fall für schwache Nerven. Aber mit gut 40`000 USD Handelsvolumen zeigte der Titel zuletzt eine ausreichende Mindestliquidität. Und die führt eben schon dazu, dass hier Bewegung reinkommt. Gestern mit 12% Plus auf neue Jahreshochs von USD 1! Wir stellen den Titel zu jedem Kurs um oder knapp unter USD 1 für spekulative Trader zum Kauf mit Kursziel USD 2. Per Ende 2000 übrigens, als die Gesellschaft zuletzt eine ähnliche Profitabilität sah wie jetzt, zahlte man schon in der Spitze bis USD 3 für den Titel! (WKN 922 675, Reuters HEMA)
Bei diesem Text handelt es sich um einen aktuellen Auszug aus dem Dienst HOT STOCKS INVESTOR, dem führenden deutschsprachigen Börsenbrief für die wachstumsstärksten Innovations- und Technologieaktien der USA.
Schon 1998 sagte HOT STOCKS INVESTOR einen Boom der Biotechbranche voraus. Damals als einziger Börseninformationsdienst in Deutschland überhaupt! In der Folgezeit versiebenfachten sich US-amerikanische Biotechaktien innerhalb von 24 Monaten. In den Folgejahren waren Leser des HOT STOCKS INVESTOR auch bei den weiteren wirtschaftlichen Megatrends INTERNET, FREIZEIT, SICHERHEIT und ENERGIE an vorderster Stelle mit dabei!
Eine solch intelligente Stock-Picking-Strategie garantiert Ihnen als Investor die Chance auf einen überdurchschnittlichen Anlageerfolg! Das Musterdepot des HOT STOCKS INVESTOR hat in den vergangenen Jahren die Nasdaq-Performance regelmäßig geschlagen, in der Spitze mit Jahresergebnissen über 100%! Auch im laufenden Jahr beweist unser Analystenteam sein Können mit einem stolzen Plus in der Depotperformance seit Jahresbeginn von +40%, während der Composite Index am Nasdaq um 10% im Minus liegt!
Einen hochexplosiven und exklusiven Titel, den spekulative Investoren ins Visier nehmen sollten, ist HEMACARE! Die kleine Gesellschaft aus Los Angeles ist im breiten Markt in der Tat so gut wie unbekannt. Kein Zufall, wird der Titel doch nur am OTC gehandelt und mit einer Market Cap von USD 7,8 Mio. im Bereich von Erinnerungswerten bewertet. Schaut man auf die fundamentale Entwicklung der letzten Jahre, verwundert das nicht, denn der Blutbankdienstleister schlitterte aufgrund problematischer Expansionsentscheidungen in eine herbe Krise, die im Vorjahr einen einschneidenden Restrukturierungskurs mit Verlusten von USD 4,7 Mio. mit sich brachte. Doch genau der zahlt sich nun aus: Die letzten drei Quartale schrieb man bei HEMACARE nun wieder zunehmend solide schwarze Zahlen: Im Q4 2003 noch USD 264`000, im Q2 2004 waren es jetzt schon USD 488`000 – damit war das Q2 jetzt das profitabelste Quartal der Gesellschaft seit dem Q4 2000! Auf Vorsteuerbasis sogar das profitabelste Quartals seit 15 Jahren. Das sieht also nach einem ordentlich gelungenen Turnaround aus. Den hat man erreicht durch Schliessungen von unrentablen Blutbanken und Fokussierung auf das Core-Business. Dadurch wird verdeckt, dass in diesen Kernbereichen auch die Umsätze sich solide entwickeln. In der Gesamtrechung zeigt sich da zwar mit Quartalsumsätzen von knapp USD 7 nicht viel im Vorjahresvergleich, betrachtet man aber die Entwicklung allein der fortgeführten Businessbereiche, verzeichnet man z.B. beim Verkauf von Blutprodukten Gewinne von über 20% zum Vorjahr! Da zahlen sich also massive Effizienzgewinne aus und die will man weiter ausbauen. Zwar hat man keine Guidance für das laufende Jahr geliefert, rechnet man aber die Entwicklung des ersten Halbjahres auf Jahresbasis hoch, erscheint ein Gewinn bei einer konservativen Schätzung von USD 1,5 Mio. als erreichbar. Bei einer optimistischen Schätzung auf der Basis allein der aktuellen Q2 Zahlen wären vielleicht sogar bis zu USD 2 Mio. drin. Und das bei einer aktuellen Market Cap von USD 7,8 Mio. – da können Sie ausrechnen, was das für einer Marktbewertung entspricht: KUV um 0,3 und KGV von 4-5. Angesichts der geringen Market Cap ist der Titel kein Fall für schwache Nerven. Aber mit gut 40`000 USD Handelsvolumen zeigte der Titel zuletzt eine ausreichende Mindestliquidität. Und die führt eben schon dazu, dass hier Bewegung reinkommt. Gestern mit 12% Plus auf neue Jahreshochs von USD 1! Wir stellen den Titel zu jedem Kurs um oder knapp unter USD 1 für spekulative Trader zum Kauf mit Kursziel USD 2. Per Ende 2000 übrigens, als die Gesellschaft zuletzt eine ähnliche Profitabilität sah wie jetzt, zahlte man schon in der Spitze bis USD 3 für den Titel! (WKN 922 675, Reuters HEMA)
Bei diesem Text handelt es sich um einen aktuellen Auszug aus dem Dienst HOT STOCKS INVESTOR, dem führenden deutschsprachigen Börsenbrief für die wachstumsstärksten Innovations- und Technologieaktien der USA.
Schon 1998 sagte HOT STOCKS INVESTOR einen Boom der Biotechbranche voraus. Damals als einziger Börseninformationsdienst in Deutschland überhaupt! In der Folgezeit versiebenfachten sich US-amerikanische Biotechaktien innerhalb von 24 Monaten. In den Folgejahren waren Leser des HOT STOCKS INVESTOR auch bei den weiteren wirtschaftlichen Megatrends INTERNET, FREIZEIT, SICHERHEIT und ENERGIE an vorderster Stelle mit dabei!
Eine solch intelligente Stock-Picking-Strategie garantiert Ihnen als Investor die Chance auf einen überdurchschnittlichen Anlageerfolg! Das Musterdepot des HOT STOCKS INVESTOR hat in den vergangenen Jahren die Nasdaq-Performance regelmäßig geschlagen, in der Spitze mit Jahresergebnissen über 100%! Auch im laufenden Jahr beweist unser Analystenteam sein Können mit einem stolzen Plus in der Depotperformance seit Jahresbeginn von +40%, während der Composite Index am Nasdaq um 10% im Minus liegt!
09/21/2004 (17:00 ET) HEMA: New 52-Wk High @ $1.420 up 2.16% - Knobias
09/20/2004 (10:50 ET) HEMA: New 52-Wk High @ $1.410 up 15.57% - Knobias
09/15/2004 (11:46 ET) HEMA: New 52-Wk High @ $1.380 up 2.22% - Knobias
09/10/2004 (10:06 ET) HEMA: Volume Spike; 144% > 20-adsv, Stock +2.97% - Knobias
09/10/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.030 up 1.98% - Knobias
JS200
09/20/2004 (10:50 ET) HEMA: New 52-Wk High @ $1.410 up 15.57% - Knobias
09/15/2004 (11:46 ET) HEMA: New 52-Wk High @ $1.380 up 2.22% - Knobias
09/10/2004 (10:06 ET) HEMA: Volume Spike; 144% > 20-adsv, Stock +2.97% - Knobias
09/10/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.030 up 1.98% - Knobias
JS200
Last Trade: 1.400 Change: 0.080 (+6.061%)
Previous Close: 1.320 Volume: 61,500
Bid: 1.320 Ask: 1.350
Today`s Open: 1.320 # of Trades: 22
JS200
Previous Close: 1.320 Volume: 61,500
Bid: 1.320 Ask: 1.350
Today`s Open: 1.320 # of Trades: 22
JS200
09/21/2004 (17:00 ET) HEMA: New 52-Wk High @ $1.420 up 2.16% - Knobias
09/20/2004 (10:50 ET) HEMA: New 52-Wk High @ $1.410 up 15.57% - Knobias
09/15/2004 (11:46 ET) HEMA: New 52-Wk High @ $1.380 up 2.22% - Knobias
09/10/2004 (10:06 ET) HEMA: Volume Spike; 144% > 20-adsv, Stock +2.97% - Knobias
09/10/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.030 up 1.98% - Knobias
JS200
09/20/2004 (10:50 ET) HEMA: New 52-Wk High @ $1.410 up 15.57% - Knobias
09/15/2004 (11:46 ET) HEMA: New 52-Wk High @ $1.380 up 2.22% - Knobias
09/10/2004 (10:06 ET) HEMA: Volume Spike; 144% > 20-adsv, Stock +2.97% - Knobias
09/10/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.030 up 1.98% - Knobias
JS200
Last Trade: 1.500 Change: 0.030 (+2.041%)
Previous Close: 1.470 Volume: 0
Bid: 1.470 Ask: 1.510
Today`s Open: N/A # of Trades: N/A
Previous Close: 1.470 Volume: 0
Bid: 1.470 Ask: 1.510
Today`s Open: N/A # of Trades: N/A
09/28/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.550 up 3.33% - Knobias
09/24/2004 (11:56 ET) HEMA: Volume Spike; 134% > 20-adsv, Stock +3.57% - Knobias
09/24/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.420 up 1.43% - Knobias
09/21/2004 (17:00 ET) HEMA: New 52-Wk High @ $1.420 up 2.16% - Knobias
09/20/2004 (10:50 ET) HEMA: New 52-Wk High @ $1.410 up 15.57% - Knobias
JS200
09/24/2004 (11:56 ET) HEMA: Volume Spike; 134% > 20-adsv, Stock +3.57% - Knobias
09/24/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.420 up 1.43% - Knobias
09/21/2004 (17:00 ET) HEMA: New 52-Wk High @ $1.420 up 2.16% - Knobias
09/20/2004 (10:50 ET) HEMA: New 52-Wk High @ $1.410 up 15.57% - Knobias
JS200
09/29/2004 (14:54 ET) HEMA: New 52-Wk High @ $1.640 up 5.81% - Knobias
09/28/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.550 up 3.33% - Knobias
09/24/2004 (11:56 ET) HEMA: Volume Spike; 134% > 20-adsv, Stock +3.57% - Knobias
09/24/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.420 up 1.43% - Knobias
09/21/2004 (17:00 ET) HEMA: New 52-Wk High @ $1.420 up 2.16% - Knobias
Last Trade: 1.640 Change: 0.090 (+5.806%)
Previous Close: 1.550 Volume: 26,900
Bid: 1.600 Ask: 1.640
Today`s Open: 1.520 # of Trades: 13
Sie steckt einfach nicht zurück
JS200
09/28/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.550 up 3.33% - Knobias
09/24/2004 (11:56 ET) HEMA: Volume Spike; 134% > 20-adsv, Stock +3.57% - Knobias
09/24/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.420 up 1.43% - Knobias
09/21/2004 (17:00 ET) HEMA: New 52-Wk High @ $1.420 up 2.16% - Knobias
Last Trade: 1.640 Change: 0.090 (+5.806%)
Previous Close: 1.550 Volume: 26,900
Bid: 1.600 Ask: 1.640
Today`s Open: 1.520 # of Trades: 13
Sie steckt einfach nicht zurück
JS200
Schlusskurs 1,65 auf Tageshöchstkurs
JS200
JS200
Last Trade: 1.650 Change: 0.100 (+6.452%)
Previous Close: 1.550 Volume: 93,800
Bid: 1.640 Ask: 1.680
Today`s Open: 1.520 # of Trades: 19
Previous Close: 1.550 Volume: 93,800
Bid: 1.640 Ask: 1.680
Today`s Open: 1.520 # of Trades: 19
09/30/2004 (16:10 ET) HEMA: New 52-Wk High @ $1.680 up 1.82% - Knobias
09/30/2004 (12:07 ET) HEMA: Filed New Form 8-K - Edgar
09/29/2004 (14:54 ET) HEMA: New 52-Wk High @ $1.640 up 5.81% - Knobias
09/28/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.550 up 3.33% - Knobias
09/24/2004 (11:56 ET) HEMA: Volume Spike; 134% > 20-adsv, Stock +3.57% - Knobias
09/30/2004 (12:07 ET) HEMA: Filed New Form 8-K - Edgar
09/29/2004 (14:54 ET) HEMA: New 52-Wk High @ $1.640 up 5.81% - Knobias
09/28/2004 (09:51 ET) HEMA: New 52-Wk High @ $1.550 up 3.33% - Knobias
09/24/2004 (11:56 ET) HEMA: Volume Spike; 134% > 20-adsv, Stock +3.57% - Knobias
Last Trade: 1.200 Change: 0.010 (+0.840%)
Previous Close: 1.190 Volume: 17,000
Bid: 1.180 Ask: 1.210
Today`s Open: 1.220 # of Trades: 7
Previous Close: 1.190 Volume: 17,000
Bid: 1.180 Ask: 1.210
Today`s Open: 1.220 # of Trades: 7
10/14/2004 (11:56 ET) HEMA: Volume Spike; 34% > 20-adsv, Stock -3.45% - Knobias
10/06/2004 (06:01 ET) HEMA: Filed New Form SC 13D - Edgar
10/05/2004 (15:17 ET) HEMA: Volume Spike; 62% > 20-adsv, Stock -18.34% - Knobias
10/04/2004 (13:45 ET) HEMA: Volume Spike; 74% > 20-adsv, Stock EVEN - Knobias
10/01/2004 (14:10 ET) HEMA: Volume Spike; 78% > 20-adsv, Stock +2.38% - Knobias
10/06/2004 (06:01 ET) HEMA: Filed New Form SC 13D - Edgar
10/05/2004 (15:17 ET) HEMA: Volume Spike; 62% > 20-adsv, Stock -18.34% - Knobias
10/04/2004 (13:45 ET) HEMA: Volume Spike; 74% > 20-adsv, Stock EVEN - Knobias
10/01/2004 (14:10 ET) HEMA: Volume Spike; 78% > 20-adsv, Stock +2.38% - Knobias
Last Trade: 1.340 Change: 0.040 (+3.077%)
Previous Close: 1.300 Volume: 8,500
Bid: 1.230 Ask: 1.340
Today`s Open: 1.300 # of Trades: 5
Previous Close: 1.300 Volume: 8,500
Bid: 1.230 Ask: 1.340
Today`s Open: 1.300 # of Trades: 5
HemaCare Corporation Schedules Investor Call for 2004 Third Quarter Financial Results
via COMTEX
November 4, 2004
LOS ANGELES, Nov 4, 2004 (BUSINESS WIRE) --
HemaCare Corporation (OTCBB:HEMA) announced today that it will release its 2004 third quarter financial results on Monday, November 15, 2004, and will be holding an interactive investor conference call at 1:00 PM (Eastern Time) to review the results. To participate in the call, please call 800-309-8563 and ask to join HemaCare`s 2004 Third Quarter Financial Results conference call. A recording will be available two hours following the call through midnight, November 19, 2004 that can be replayed by calling 800-642-1687, ID number 2019588.
About HemaCare Corporation
Founded in 1978, HemaCare is a national provider of blood products and services and the only publicly traded company engaged in the blood services industry in the U.S. HemaCare is licensed by the FDA and accredited by the American Association of Blood Banks. The Company focuses on providing cost effective, high quality solutions to the blood-related needs of U.S. hospitals.
This press release contains "forward-looking statements" under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.) Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words "anticipates," "expects," "intends," "plans" and variations and similar expressions. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation the Company`s need to successfully complete its operating plan to improve profit; the potential loss of the Company`s lines of credit; the potential inability of the Company to meet future capital needs; increasing costs that the Company may not be able to pass on to customers because the market price for blood does not necessarily reflect the costs of collecting and processing it; declining blood donations; the Company`s dependence on reimbursement rates of third party providers; its increasing reliance on outside laboratories; limited access to insurance; the competitive advantage enjoyed by not-for-profit companies; potential changes in the healthcare industry; future technology for blood collection and blood replacement; the need to obtain services of qualified medical professionals; the impact of heavy regulation in the Company`s industry; potential liability for undetected blood pathogens and other product safety and liability concerns; environment risks associated with biohazardous substances; the threat of business interruption due to terrorism and the security measures taken in response to terrorism; the provisions of the Company`s charter documents that might delay or prevent an acquisition or sale of the Company; lack of liquidity and market risk associated with OTC Bulletin Board stocks; volatility in our stock price; potential dilution that could result from future sales of the Company`s common stock; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
SOURCE: HemaCare Corporation
HemaCare Corporation JoAnn Mannise, 877-310-0717 www.hemacare.com
Copyright (C) 2004 Business Wire. All rights reserved.
via COMTEX
November 4, 2004
LOS ANGELES, Nov 4, 2004 (BUSINESS WIRE) --
HemaCare Corporation (OTCBB:HEMA) announced today that it will release its 2004 third quarter financial results on Monday, November 15, 2004, and will be holding an interactive investor conference call at 1:00 PM (Eastern Time) to review the results. To participate in the call, please call 800-309-8563 and ask to join HemaCare`s 2004 Third Quarter Financial Results conference call. A recording will be available two hours following the call through midnight, November 19, 2004 that can be replayed by calling 800-642-1687, ID number 2019588.
About HemaCare Corporation
Founded in 1978, HemaCare is a national provider of blood products and services and the only publicly traded company engaged in the blood services industry in the U.S. HemaCare is licensed by the FDA and accredited by the American Association of Blood Banks. The Company focuses on providing cost effective, high quality solutions to the blood-related needs of U.S. hospitals.
This press release contains "forward-looking statements" under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.) Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words "anticipates," "expects," "intends," "plans" and variations and similar expressions. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation the Company`s need to successfully complete its operating plan to improve profit; the potential loss of the Company`s lines of credit; the potential inability of the Company to meet future capital needs; increasing costs that the Company may not be able to pass on to customers because the market price for blood does not necessarily reflect the costs of collecting and processing it; declining blood donations; the Company`s dependence on reimbursement rates of third party providers; its increasing reliance on outside laboratories; limited access to insurance; the competitive advantage enjoyed by not-for-profit companies; potential changes in the healthcare industry; future technology for blood collection and blood replacement; the need to obtain services of qualified medical professionals; the impact of heavy regulation in the Company`s industry; potential liability for undetected blood pathogens and other product safety and liability concerns; environment risks associated with biohazardous substances; the threat of business interruption due to terrorism and the security measures taken in response to terrorism; the provisions of the Company`s charter documents that might delay or prevent an acquisition or sale of the Company; lack of liquidity and market risk associated with OTC Bulletin Board stocks; volatility in our stock price; potential dilution that could result from future sales of the Company`s common stock; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
SOURCE: HemaCare Corporation
HemaCare Corporation JoAnn Mannise, 877-310-0717 www.hemacare.com
Copyright (C) 2004 Business Wire. All rights reserved.
11/12/2004 (13:00 ET) HEMA: To Release Q3 Results Nov 15 [BMO] - Knobias
11/04/2004 (08:01 ET) HemaCare Corporation Schedules Investor Call for 2004 Third Quarter Financial Results - Business Wire
JS200
11/04/2004 (08:01 ET) HemaCare Corporation Schedules Investor Call for 2004 Third Quarter Financial Results - Business Wire
JS200
11/15/2004 (10:02 ET) HEMA: Q3 Earnings Call @ 13:00 ET Today - Knobias
11/15/2004 (09:56 ET) HEMA: Volume Spike; 110% > 20-adsv, Stock +3.45% - Knobias
11/15/2004 (08:29 ET) HEMA: Q3 Results 6c vs (60c); EPS +110% Y/Y; No Guidance - Knobias
11/15/2004 (08:03 ET) HemaCare Reports Third Quarter Financial Results - Business Wire
11/15/2004 (06:50 ET) TABLE: Confirmed Earnings Expected Monday, Nov 15 - Knobias
JS200
11/15/2004 (09:56 ET) HEMA: Volume Spike; 110% > 20-adsv, Stock +3.45% - Knobias
11/15/2004 (08:29 ET) HEMA: Q3 Results 6c vs (60c); EPS +110% Y/Y; No Guidance - Knobias
11/15/2004 (08:03 ET) HemaCare Reports Third Quarter Financial Results - Business Wire
11/15/2004 (06:50 ET) TABLE: Confirmed Earnings Expected Monday, Nov 15 - Knobias
JS200
11/16/2004 (15:31 ET) HEMA: Filed New Form 10-K/A, Annual Report - Knobias
11/16/2004 (07:34 ET) HEMA: Filed 8-K Regarding 3rd Qtr Results & Conf Call (Nov-15 PR) - Knobias
11/16/2004 (06:08 ET) HEMA: Filed New Form 8-K, Material Event Disclosure - Knobias
11/15/2004 (17:27 ET) HEMA: Filed New Form 10-Q, Quarterly Report - Knobias
11/15/2004 (10:02 ET) HEMA: Q3 Earnings Call @ 13:00 ET Today - Knobias
11/16/2004 (07:34 ET) HEMA: Filed 8-K Regarding 3rd Qtr Results & Conf Call (Nov-15 PR) - Knobias
11/16/2004 (06:08 ET) HEMA: Filed New Form 8-K, Material Event Disclosure - Knobias
11/15/2004 (17:27 ET) HEMA: Filed New Form 10-Q, Quarterly Report - Knobias
11/15/2004 (10:02 ET) HEMA: Q3 Earnings Call @ 13:00 ET Today - Knobias
Last Trade: 1.500 Change: 0.050 (+3.448%)
Previous Close: 1.450 Volume: 0
Bid: 1.450 Ask: 1.510
Today`s Open: N/A # of Trades: N/A
Previous Close: 1.450 Volume: 0
Bid: 1.450 Ask: 1.510
Today`s Open: N/A # of Trades: N/A
Last Trade: 1.470 Change: 0.000 (+0.000%)
Previous Close: 1.470 Volume: 3,000
Bid: 1.450 Ask: 1.500
Today`s Open: 1.450 # of Trades: 5
Previous Close: 1.470 Volume: 3,000
Bid: 1.450 Ask: 1.500
Today`s Open: 1.450 # of Trades: 5
HemaCare Reports Fourth Quarter and Full Year 2004 Financial Results
via COMTEX
March 24, 2005
LOS ANGELES, Mar 24, 2005 (BUSINESS WIRE) --
HemaCare Corporation (OTCBB:HEMA) announced today results of operations for the fourth quarter and the year ended December 31, 2004. For the quarter, the Company reported net income of $336,000, or $.05 per share basic and $.04 per share fully diluted, on revenue of $6.9 million. The reported fourth quarter net income represents a $72,000, or 27.3%, improvement over the same quarter of 2003 with revenues increasing $221,000, or 3.3%. The improvement in net income is due to an increase in blood products revenue from the Company`s California and Maine operations.
For the year ended December 31, 2004, the Company reported net income of $1,545,000, or $0.20 per share basic and $0.19 per share diluted, compared to a net loss for 2003 of $4,679,000, or $0.60 per share basic and diluted. The turn around in performance from 2003 to 2004 was the result of the successful implementation of management`s restructuring plan initiated in the third quarter of 2003. This plan closed underperforming operations, reduced overhead costs and enabled management to focus greater attention on growing the remaining operations. In addition, since the Company wrote-down 100% of the Company`s deferred tax assets of $2,984,000 in 2003, the Company did not experience any further write-down in these assets in 2004. Finally, the Company recorded a one-time benefit in 2004 of $167,000 as a result of the receipt of a refund of previously paid sales taxes from one of the Company`s major vendors.
While revenue for the Company`s blood services business segment was stable, increasing 0.4% from 2003 to 2004, the Company`s blood products segment decreased 3.4%. Ongoing blood products operations reported increased revenue of $2,945,000, or 18.9%, over this same period. Gross profit for the Company`s blood services segment improved a modest 1.5% from 2003 to 2004, while gross profit for the ongoing blood products operations increased 196% to $3,205,000 in 2004 from $1,082,000 in 2003. This improvement is the result of the elimination of management distraction associated with the underperforming donor centers that were closed in late 2003. This enabled management to focus in 2004 on improving the performance of the remaining blood products operations.
General and administrative expenses increased $474,000, or 12%, to $4,420,000 from $3,946,000 in 2003. This is mostly attributable to the reclassification of liability insurance in 2004 to general and administrative expenses from operating costs as recorded in prior years, an increase in overall insurance expense, higher staff recruitment costs and an increase in management bonuses.
Commenting on the 2004 results, Judi Irving, President and Chief Executive Officer, stated, "We are very pleased with the tremendous improvement in the overall performance of the Company. Management and staff have worked long and hard to achieve these results, which on a pretax basis, represent the best calendar year earnings ever reported in the Company`s history. Our ongoing blood products operations are well positioned going into 2005. However, the recent addition of new competition in the blood services market could negatively impact future profitability for this business segment. Management remains focused on continuing to improve every aspect of our operations. We intend to move forward with the necessary investments in deferred infrastructure projects to enhance the Company`s prospects for future profitability."
HemaCare will be holding an interactive investor conference call on Thursday, March 24, 2005 at 1:00 pm (Eastern Standard Time). Judi Irving, President and CEO, and Robert Chilton, Executive Vice President and Chief Financial Officer, will review the 2004 financial results. To participate in the call, please call 800-309-8563 and ask to join HemaCare`s 2004 annual earnings conference call. A recording will be available two hours following the call through midnight, March 31, 2005 that can be replayed by calling 800-642-1687, ID number 4620718. After March 31, 2005, the recording will be available on the Company`s web site, www.Hemacare.com.
ABOUT HEMACARE CORPORATION
Founded in 1978, HemaCare is a provider of blood products and services. HemaCare is licensed by the FDA and accredited by the American Association of Blood Banks. The Company focuses on providing cost effective and high quality solutions to organizations with blood-related needs.
This press release contains "forward-looking statements" under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words "anticipates," "expects," "intends," "plans" and similar expressions. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation, the Company`s need to successfully complete its operating plan to improve profits; the potential loss of the Company`s lines of credit; the potential inability of the Company to meet future capital needs; increasing costs that the Company may not be able to pass on to customers because the market price for blood does not necessarily reflect the costs of collecting and processing it; declining blood donations; the Company`s dependence on reimbursement rates of third party providers; its increasing reliance on outside laboratories; limited access to insurance; the competitive advantage enjoyed by not-for-profit companies; potential changes in the healthcare industry; future technology for blood collection and blood replacement; the need to obtain services of qualified medical professionals; the impact of heavy regulation in the Company`s industry; potential liability for undetected blood pathogens and other product safety and liability concerns; environmental risks associated with biohazardous substances; the threat of business interruption due to terrorism and the security measures taken in response to terrorism; the provisions of the Company`s charter documents that might delay or prevent an acquisition or sale of the Company; lack of liquidity and market risk associated with OTC Bulletin Board stocks; volatility in our stock price; potential dilution that could result from future sales of the Company`s common stock; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
HemaCare Corporation Condensed Consolidated Data (Unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2004 2003 2004 2003 ------------- ------------ ------------ ------------Statements of Income (Operations):Revenues $6,861,000 $6,640,000 $26,836,000 $27,488,000Gross Profit $1,512,000 $1,107,000 $5,816,000 $2,251,000 ------------- ------------ ------------ ------------General and administrative expenses $1,158,000 $843,000 $4,420,000 $3,946,000Other Income $- $- $167,000 $- ------------- ------------ ------------ ------------Income (loss) before income taxes $354,000 $264,000 $1,563,000 $(1,695,000)Provision for income taxes $18,000 $- $18,000 $2,984,000 ------------- ------------ ------------ ------------Net income (loss) $336,000 $264,000 $1,545,000 $(4,679,000) ============= ============ ============ ============Basic earnings (loss) per share(a) $0.05 $0.04 $0.20 $(0.60) ============= ============ ============ ============Diluted earnings (loss) per share(a) $0.04 $0.04 $0.19 $(0.60) ============= ============ ============ ============Weighted average shares outstanding - basic 8,013,000 7,756,000 7,831,000 7,753,000 ============= ============ ============ ============Weighted average shares outstanding - diluted 8,689,000 8,040,000 8,237,000 7,753,000 ============= ============ ============ ============(a)Earnings per share adjusted to reflect quarterly amount for proper representation of annual earnings per share. Some rounding differences may exist. December 31, December 31, 2004 2003 ------------- ------------Balance Sheets:AssetsCash and cash equivalents $2,082,000 $935,000Other current assets 4,455,000 4,030,000Non-current assets 2,807,000 3,321,000 ------------- ------------Total assets $9,344,000 $8,286,000 ============= ============Liabilities and Shareholders` EquityCurrent liabilities $3,469,000 $3,786,000Long-term liabilities 708,000 1,089,000Shareholders` equity 5,167,000 3,411,000 ------------- ------------Total liabilities and shareholders` equity $9,344,000 $8,286,000 ============= ============
SOURCE: HemaCare Corporation
HemaCare Corporation Robert S. Chilton, 877-310-0717 www.hemacare.com
Copyright Business Wire 2005
Print story
Current Quote
OBB: HEMA
Biotech/Medical
Last: 1.650
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A
First Alert News
Get real-time HEMA release alerts by entering your email address below.
JS200
via COMTEX
March 24, 2005
LOS ANGELES, Mar 24, 2005 (BUSINESS WIRE) --
HemaCare Corporation (OTCBB:HEMA) announced today results of operations for the fourth quarter and the year ended December 31, 2004. For the quarter, the Company reported net income of $336,000, or $.05 per share basic and $.04 per share fully diluted, on revenue of $6.9 million. The reported fourth quarter net income represents a $72,000, or 27.3%, improvement over the same quarter of 2003 with revenues increasing $221,000, or 3.3%. The improvement in net income is due to an increase in blood products revenue from the Company`s California and Maine operations.
For the year ended December 31, 2004, the Company reported net income of $1,545,000, or $0.20 per share basic and $0.19 per share diluted, compared to a net loss for 2003 of $4,679,000, or $0.60 per share basic and diluted. The turn around in performance from 2003 to 2004 was the result of the successful implementation of management`s restructuring plan initiated in the third quarter of 2003. This plan closed underperforming operations, reduced overhead costs and enabled management to focus greater attention on growing the remaining operations. In addition, since the Company wrote-down 100% of the Company`s deferred tax assets of $2,984,000 in 2003, the Company did not experience any further write-down in these assets in 2004. Finally, the Company recorded a one-time benefit in 2004 of $167,000 as a result of the receipt of a refund of previously paid sales taxes from one of the Company`s major vendors.
While revenue for the Company`s blood services business segment was stable, increasing 0.4% from 2003 to 2004, the Company`s blood products segment decreased 3.4%. Ongoing blood products operations reported increased revenue of $2,945,000, or 18.9%, over this same period. Gross profit for the Company`s blood services segment improved a modest 1.5% from 2003 to 2004, while gross profit for the ongoing blood products operations increased 196% to $3,205,000 in 2004 from $1,082,000 in 2003. This improvement is the result of the elimination of management distraction associated with the underperforming donor centers that were closed in late 2003. This enabled management to focus in 2004 on improving the performance of the remaining blood products operations.
General and administrative expenses increased $474,000, or 12%, to $4,420,000 from $3,946,000 in 2003. This is mostly attributable to the reclassification of liability insurance in 2004 to general and administrative expenses from operating costs as recorded in prior years, an increase in overall insurance expense, higher staff recruitment costs and an increase in management bonuses.
Commenting on the 2004 results, Judi Irving, President and Chief Executive Officer, stated, "We are very pleased with the tremendous improvement in the overall performance of the Company. Management and staff have worked long and hard to achieve these results, which on a pretax basis, represent the best calendar year earnings ever reported in the Company`s history. Our ongoing blood products operations are well positioned going into 2005. However, the recent addition of new competition in the blood services market could negatively impact future profitability for this business segment. Management remains focused on continuing to improve every aspect of our operations. We intend to move forward with the necessary investments in deferred infrastructure projects to enhance the Company`s prospects for future profitability."
HemaCare will be holding an interactive investor conference call on Thursday, March 24, 2005 at 1:00 pm (Eastern Standard Time). Judi Irving, President and CEO, and Robert Chilton, Executive Vice President and Chief Financial Officer, will review the 2004 financial results. To participate in the call, please call 800-309-8563 and ask to join HemaCare`s 2004 annual earnings conference call. A recording will be available two hours following the call through midnight, March 31, 2005 that can be replayed by calling 800-642-1687, ID number 4620718. After March 31, 2005, the recording will be available on the Company`s web site, www.Hemacare.com.
ABOUT HEMACARE CORPORATION
Founded in 1978, HemaCare is a provider of blood products and services. HemaCare is licensed by the FDA and accredited by the American Association of Blood Banks. The Company focuses on providing cost effective and high quality solutions to organizations with blood-related needs.
This press release contains "forward-looking statements" under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words "anticipates," "expects," "intends," "plans" and similar expressions. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation, the Company`s need to successfully complete its operating plan to improve profits; the potential loss of the Company`s lines of credit; the potential inability of the Company to meet future capital needs; increasing costs that the Company may not be able to pass on to customers because the market price for blood does not necessarily reflect the costs of collecting and processing it; declining blood donations; the Company`s dependence on reimbursement rates of third party providers; its increasing reliance on outside laboratories; limited access to insurance; the competitive advantage enjoyed by not-for-profit companies; potential changes in the healthcare industry; future technology for blood collection and blood replacement; the need to obtain services of qualified medical professionals; the impact of heavy regulation in the Company`s industry; potential liability for undetected blood pathogens and other product safety and liability concerns; environmental risks associated with biohazardous substances; the threat of business interruption due to terrorism and the security measures taken in response to terrorism; the provisions of the Company`s charter documents that might delay or prevent an acquisition or sale of the Company; lack of liquidity and market risk associated with OTC Bulletin Board stocks; volatility in our stock price; potential dilution that could result from future sales of the Company`s common stock; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
HemaCare Corporation Condensed Consolidated Data (Unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2004 2003 2004 2003 ------------- ------------ ------------ ------------Statements of Income (Operations):Revenues $6,861,000 $6,640,000 $26,836,000 $27,488,000Gross Profit $1,512,000 $1,107,000 $5,816,000 $2,251,000 ------------- ------------ ------------ ------------General and administrative expenses $1,158,000 $843,000 $4,420,000 $3,946,000Other Income $- $- $167,000 $- ------------- ------------ ------------ ------------Income (loss) before income taxes $354,000 $264,000 $1,563,000 $(1,695,000)Provision for income taxes $18,000 $- $18,000 $2,984,000 ------------- ------------ ------------ ------------Net income (loss) $336,000 $264,000 $1,545,000 $(4,679,000) ============= ============ ============ ============Basic earnings (loss) per share(a) $0.05 $0.04 $0.20 $(0.60) ============= ============ ============ ============Diluted earnings (loss) per share(a) $0.04 $0.04 $0.19 $(0.60) ============= ============ ============ ============Weighted average shares outstanding - basic 8,013,000 7,756,000 7,831,000 7,753,000 ============= ============ ============ ============Weighted average shares outstanding - diluted 8,689,000 8,040,000 8,237,000 7,753,000 ============= ============ ============ ============(a)Earnings per share adjusted to reflect quarterly amount for proper representation of annual earnings per share. Some rounding differences may exist. December 31, December 31, 2004 2003 ------------- ------------Balance Sheets:AssetsCash and cash equivalents $2,082,000 $935,000Other current assets 4,455,000 4,030,000Non-current assets 2,807,000 3,321,000 ------------- ------------Total assets $9,344,000 $8,286,000 ============= ============Liabilities and Shareholders` EquityCurrent liabilities $3,469,000 $3,786,000Long-term liabilities 708,000 1,089,000Shareholders` equity 5,167,000 3,411,000 ------------- ------------Total liabilities and shareholders` equity $9,344,000 $8,286,000 ============= ============
SOURCE: HemaCare Corporation
HemaCare Corporation Robert S. Chilton, 877-310-0717 www.hemacare.com
Copyright Business Wire 2005
Print story
Current Quote
OBB: HEMA
Biotech/Medical
Last: 1.650
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A
First Alert News
Get real-time HEMA release alerts by entering your email address below.
JS200
RAiDAR alerts Learn More About RAiDAR-LT
03/24/2005 (09:02 ET) HEMA: Q4 Results 4c vs 4c; EPS 0% Y/Y; No Guidance - Knobias
03/24/2005 (09:00 ET) HemaCare Reports Fourth Quarter and Full Year 2004 Financial Results - Business Wire
03/24/2005 (06:30 ET) TABLE: Confirmed Earnings Expected Thursday, Mar 24 - Knobias
03/24/2005 (06:00 ET) HEMA: To Release Q4 Results Mar 24 [BMO] - Knobias
03/24/2005 (01:09 ET) FirstAlert: 12-1 P.M. Investrend / Bestcalls - Investrend
03/23/2005 (19:07 ET) MARKET: After Hours News & Late Trading - Knobias
03/23/2005 (13:00 ET) HEMA: To Release Q4 Results Mar 24 [BMO] - Knobias
03/18/2005 (18:45 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:36 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:34 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:32 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:07 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (17:03 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (15:44 ET) HEMA: New Form 5 Filed, Beneficial Ownership Annual Statement - Edgar
03/09/2005 (16:25 ET) HEMA: Filed New Form SC 13G/A, Beneficial Ownership Disclosure - Edgar
03/07/2005 (14:00 ET) HemaCare Corporation Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2004 Annual Financial Results - Business Wire
01/19/2005 (10:15 ET) HEMA: Volume Spike; 49% > 20-adsv, Stock +4.79% - Knobias
01/19/2005 (09:51 ET) HEMA: New 52-Wk High @ $1.970 up 4.79% - Knobias
01/18/2005 (09:51 ET) HEMA: New 52-Wk High @ $1.800 up 12.50% - Knobias
01/18/2005 (09:51 ET) HEMA: Volume Spike; 147% > 20-adsv, Stock +11.87% - Knobias
12/29/2004 (12:55 ET) HEMA: Volume Spike; 122% > 20-adsv, Stock +10.34% - Knobias
12/20/2004 (16:13 ET) HEMA: Filed New Form SC 13G, Beneficial Ownership Disclosure - Edgar
11/30/2004 (13:17 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/16/2004 (15:31 ET) HEMA: Filed New Form 10-K/A, Annual Report - Knobias
11/16/2004 (07:34 ET) HEMA: Filed 8-K Regarding 3rd Qtr Results & Conf Call (Nov-15 PR) - Knobias
03/24/2005 (09:02 ET) HEMA: Q4 Results 4c vs 4c; EPS 0% Y/Y; No Guidance - Knobias
03/24/2005 (09:00 ET) HemaCare Reports Fourth Quarter and Full Year 2004 Financial Results - Business Wire
03/24/2005 (06:30 ET) TABLE: Confirmed Earnings Expected Thursday, Mar 24 - Knobias
03/24/2005 (06:00 ET) HEMA: To Release Q4 Results Mar 24 [BMO] - Knobias
03/24/2005 (01:09 ET) FirstAlert: 12-1 P.M. Investrend / Bestcalls - Investrend
03/23/2005 (19:07 ET) MARKET: After Hours News & Late Trading - Knobias
03/23/2005 (13:00 ET) HEMA: To Release Q4 Results Mar 24 [BMO] - Knobias
03/18/2005 (18:45 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:36 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:34 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:32 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (18:07 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (17:03 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Edgar
03/18/2005 (15:44 ET) HEMA: New Form 5 Filed, Beneficial Ownership Annual Statement - Edgar
03/09/2005 (16:25 ET) HEMA: Filed New Form SC 13G/A, Beneficial Ownership Disclosure - Edgar
03/07/2005 (14:00 ET) HemaCare Corporation Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2004 Annual Financial Results - Business Wire
01/19/2005 (10:15 ET) HEMA: Volume Spike; 49% > 20-adsv, Stock +4.79% - Knobias
01/19/2005 (09:51 ET) HEMA: New 52-Wk High @ $1.970 up 4.79% - Knobias
01/18/2005 (09:51 ET) HEMA: New 52-Wk High @ $1.800 up 12.50% - Knobias
01/18/2005 (09:51 ET) HEMA: Volume Spike; 147% > 20-adsv, Stock +11.87% - Knobias
12/29/2004 (12:55 ET) HEMA: Volume Spike; 122% > 20-adsv, Stock +10.34% - Knobias
12/20/2004 (16:13 ET) HEMA: Filed New Form SC 13G, Beneficial Ownership Disclosure - Edgar
11/30/2004 (13:17 ET) HEMA: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/16/2004 (15:31 ET) HEMA: Filed New Form 10-K/A, Annual Report - Knobias
11/16/2004 (07:34 ET) HEMA: Filed 8-K Regarding 3rd Qtr Results & Conf Call (Nov-15 PR) - Knobias
03/24/2005 (10:21 ET) MARKET: Indices Higher; LEXR Awarded $380M Verdict - Knobias
03/24/2005 (10:02 ET) HEMA: Q4 Earnings Call @ 13:00 ET Today - Knobias
03/24/2005 (09:02 ET) HEMA: Q4 Results 4c vs 4c; EPS 0% Y/Y; No Guidance - Knobias
03/24/2005 (09:00 ET) HemaCare Reports Fourth Quarter and Full Year 2004 Financial Results - Business Wire
03/24/2005 (01:09 ET) FirstAlert: 12-1 P.M. Investrend / Bestcalls - Investrend
03/24/2005 (10:02 ET) HEMA: Q4 Earnings Call @ 13:00 ET Today - Knobias
03/24/2005 (09:02 ET) HEMA: Q4 Results 4c vs 4c; EPS 0% Y/Y; No Guidance - Knobias
03/24/2005 (09:00 ET) HemaCare Reports Fourth Quarter and Full Year 2004 Financial Results - Business Wire
03/24/2005 (01:09 ET) FirstAlert: 12-1 P.M. Investrend / Bestcalls - Investrend
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,23 | |
| - | |
| 0,00 | |
| - | |
| 0,00 | |
| +9.900,00 | |
| - | |
| -2,70 | |
| -10,53 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 245 | ||
| 99 | ||
| 83 | ||
| 79 | ||
| 75 | ||
| 52 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 33 |
